Figure 1 - available via license: Creative Commons Attribution 3.0 Unported
Content may be subject to copyright.
Flowchart for the selection of included trials. 

Flowchart for the selection of included trials. 

Source publication
Article
Full-text available
To evaluate the efficacy and safety of antibody induction therapies in kidney transplantation. Systematic literature searches were undertaken using MEDLINE, Embase, and Cochrane Library database from 1980 to 2016. Randomized controlled trials (RCTs) comparing three antibody induction therapies (alemtuzumab, interleukin-2 receptor antibodies and ant...

Contexts in source publication

Context 1
... used many logic combinations of keywords and text words to search the Pubmed, Embase and Cochrane library as well as related interventions and randomized controlled trials till August 2016 (see Supplementary Appendix 1). Also, we also searched the websites manually as follows: Current Controlled Trials, ClinicalTrials.gov and The World Health Organization International Clinical Trials ...
Context 2
... the increased numbers of new trials, this manuscript intends to compare the treatment outcome of alemtuzumab with other induction drugs such as basiliximab, daclizumab and ATG in kidney transplant for all RCTs using the Bayesian network meta-analysis [28][29][30][31]. Our study will provide useful information for transplant physicians. Figure 1 showed how we select the required trials in this study. In the original database and website searching we found 4380 records and then we discarded the duplicates, 2630 records were left. After 2443 records were eliminated, then 187 full-text were used for quantification. At last, 23 studies were included in this research [13-17, 19-20, 32-47]. The details of the selected studies were listed in Table 1. Nine studies were identified as low quality (score ≤ 3), and the rest were medium quality (scored 4 or 5) which can be seen in the methodological quality assessment (Table 2). 3444 kidney transplant recipients from eighteen studies were available for network meta-analysis [14-17, 20, 32-44]. Figure 2 was the comparisons structure of the primary ...

Similar publications

Article
Full-text available
Background Several disease-modifying drug therapies are available for the treatment of multiple sclerosis (MS). To ensure the most appropriate MS management, we assessed the effectiveness and cost-effectiveness of the disease-modifying medicines used for MS. Methods We conducted a systematic review including 11 disease-modifying drugs used for tre...

Citations

... According to a prospective, randomized study, patients receiving anti-thymocyte globulin presented a greater incidence of infection (85.8%) compared to those with basiliximab (75.2%) at 12 months after transplantation [37]. However, there was no significant difference in patient survival, similar to the results of a recent study using a network metaanalysis [38]. In Korea, the one-year patient survival in the anti-thymocyte globulin group (89.4%) was compared to the basiliximab group (93.8%), and presented no significant difference [39]. ...
Article
Full-text available
Mortality at an early stage after kidney transplantation is a catastrophic event. Treatment-related mortality (TRM) within 1 or 3 months after kidney transplantation has been seldom reported. We designed a retrospective observational cohort study using a national population-based database, which included information about all kidney recipients between 2003 and 2016. A total of 16,073 patients who underwent kidney transplantation were included. The mortality rates 1 month (early TRM) and 3 months (TRM) after transplantation were 0.5% (n = 74) and 1.0% (n = 160), respectively. Based on a multivariate analysis, older age (hazard ratio [HR] = 1.06; P < 0.001), coronary artery disease (HR = 3.02; P = 0.002), and hemodialysis compared with pre-emptive kidney transplantation (HR = 2.53; P = 0.046) were the risk factors for early TRM. Older age (HR = 1.07; P < 0.001), coronary artery disease (HR = 2.88; P < 0.001), and hemodialysis (HR = 2.35; P = 0.004) were the common independent risk factors for TRM. In contrast, cardiac arrhythmia (HR = 1.98; P = 0.027) was associated only with early TRM, and fungal infection (HR = 2.61; P < 0.001), and epoch of transplantation (HR = 0.34; P < 0.001) were the factors associated with only TRM. The identified risk factors should be considered in patient counselling, selection, and management to prevent TRM.